Míriam Molina‐Arcas

Author

Míriam Molina‐Arcas

Also Known As

Gita Mistry, Kylie Montgomery, M Gomez Molina, M Molina-Arcas, M. Molina, M. Molina-Arcas, Miriam Gómez Molina, Miriam Molina, Miriam Molina-Arcas, Miriam Molina‐Arcas

182

Publications

4.6K

Citations

H-Index

Concepts

All Affiliations

The Francis Crick Institute Universitat de Barcelona Institute of Cancer Research Cancer Research UK University College London

About

Míriam Molina‐Arcas is an author at The Francis Crick Institute specializing in medicine, cell biology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	734
2	Natural Sciences	2	2	88
3	Public Health	1	1	14
4	Social Sciences	1	1	28
5	Biochemistry	1	1	46

Míriam Molina‐Arcas

Publications

3.5K

Citations

H-Index

Page 1

	Year	Citations
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA Matthew A. Coelho, Sophie de Carné Trécesson, Sareena Rana, Immunity	2017	644
The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer Madhu Kumar, David C. Hancock, Míriam Molina‐Arcas, Cell OncologyOncogenic AgentMedicineRadiation OncologyCancer Biology	2012	266
RETRACTED ARTICLE: Antibodies against endogenous retroviruses promote lung cancer immunotherapy Kevin W. Ng, Jesse Boumelha, Katey S.S. Enfield, Nature	2023	240
Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer Míriam Molina‐Arcas, Christopher Moore, Sareena Rana, Science Translational Medicine	2019	219
Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity. José Manuel García-Manteiga, Míriam Molina‐Arcas, F. Javier Casado, PubMed	2003	213
Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies Michael Steckel, Míriam Molina‐Arcas, Britta Weigelt, Cell Research Synthetic Lethal InteractionsTherapeutic Targeting StrategiesCancer BiologyTumor BiologyAnti-cancer Agent	2012	187
Coordinate Direct Input of Both KRAS and IGF1 Receptor to Activation of PI3 kinase in <i>KRAS</i> -Mutant Lung Cancer Míriam Molina‐Arcas, David C. Hancock, Clare Sheridan, Cancer Discovery	2013	163
RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance Daniël A. Lionarons, David C. Hancock, Sareena Rana, Cancer Cell	2019	131
Transport of Lamivudine [(-)-β-l-2′,3′-Dideoxy-3′-thiacytidine] and High-Affinity Interaction of Nucleoside Reverse Transcriptase Inhibitors with Human Organic Cation Transporters 1, 2, and 3 Gerard Minuesa, Christopher Volk, Míriam Molina‐Arcas, Journal of Pharmacology and Experimental Therapeutics	2009	130
Therapeutic KRAS <sup>G12C</sup> inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers Edurne Mugarza, Febe van Maldegem, Jesse Boumelha, Science Advances	2022	119

Page 1